, J. Thromb. Haemost
, , 2005.
, Factor IX variants improve gene therapy efficacy for hemophilia B. Blood
, , vol.8
, , p.9
An RNAi therapeutic (n=8/group). Data represent mean±SD. 18 (n=5/group) 8 weeks post-AAV administration. Data represent mean±SD, 2015. ,